Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share ofMAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report.

The details can be read here.